Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 juin 2025 07h00 HE | Source: Lungpacer Medical USA Inc.

American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System's Breakthrough Results in Ventilator Weaning

EXTON, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical, Inc., a pioneering medical device company focused on neurostimulation therapies for critical care patients, today announced the...
19 mai 2025 08h00 HE | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
14 mai 2025 08h00 HE | Source: aTyr Pharma, Inc.

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
06 mai 2025 04h00 HE | Source: ENA Respiratory

ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer

MELBOURNE, Australia, May 06, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral...
01 mai 2025 09h00 HE | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD...
28 avr. 2025 07h00 HE | Source: Lungpacer Medical USA Inc.

Lungpacer to Showcase the Potential of Novel Technologies to Improve Lung, Heart, and Brain Health in Ventilated Patients

This spring, Lungpacer Medical clinical experts and device innovators will be featured presenters at top industry events.
09 avr. 2025 04h00 HE | Source: ENA Respiratory

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy to be led by global health physician scientist, Dr. Justin...
02 avr. 2025 04h00 HE | Source: ENA Respiratory

ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults

Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adultsAdministration of INNA-051 to older adults (65 years old) in a Phase 1 study was...
28 mars 2025 02h00 HE | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for...
24 mars 2025 07h00 HE | Source: Lungpacer Medical USA Inc.

Kevin Kearney Joins Lungpacer Medical as Chief Commercial Officer

Lungpacer Medical Appoints Medical Device and Healthcare Industry Veteran with 20 Years of Experience as CCO

Page suivante keyboard_arrow_right